Polymorphisms in DNA repair genes and associations with cancer risk.

By Ellen L. Goode, C. Ulrich, John D. Potter. Cancer Epidemiology, Biomarkers and Prevention, 2002

1,299 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Drug Resistance in Cancer: An Overview (2014, background): “Dysregulation or impairment of certain DDR genes and mechanisms either by mutations or epigenetic silencing are common in many cancers [54–56].”
Revisiting the hallmarks of cancer. (2017, unknown): “Acquired cancers have also been shown to exhibit defects in repair pathways as they evolve [45], and polymorphisms involving repair genes have been correlated to cancer risk; those are probably further responsible for variability of therapeutic response (since most anti-cancer therapies function by ”
Oxidative Stress and Oxidative Damage in Carcinogenesis (2010, result): “…Asp148Glu are the two most common SNPs. Associations between polymorphisms in APE1 and increased risk of lung, colon, breast, SCCHN, prostate, and pancreatic cancer have been reported, but with mixed results (Goode, Ulrich, and Potter 2002; Zhang et al. 2004; Hung et al. 2005; Jiao et al. 2006).”